Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Naoxintong capsule decreases circulating exosomes of miR-382-5p to protect LPS-induced vascular endothelial cell injury by targeting <i>STC1 in vitro</i>

Xu Z., Wu H., Fan W., Meng F., Hu S., Zou M.

Laboratory Study on Face & Skin, published in Front Pharmacol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Pharmacol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41878333
PMCID
PMC13006496
DOI
10.3389/fphar.2026.1655883

Abstract (original English)

Background Cardiovascular and cerebrovascular diseases, major health threats in aging populations, involve vascular endothelial injury as a key pathological factor. Circulating exosomes, a type of extracellular vesicles involved in substance transport and signal transduction, serve as regulatory mediators in vascular diseases. Naoxintong Capsule (NXT), a traditional Chinese medicine with 3 decades of clinical application, protects vascular diseases via multifaceted mechanisms, yet its circulating exosome-mediated endothelial protection remains unclear. Methods Circulating exosomes were isolated from NXT-treated (NXT-Exo) and saline-treated (Ctl-Exo) SD rats. The effect of NXT-Exo and Ctl-Exo on lipopolysaccharide (LPS) induced human microvascular endothelial cells (HMEC-1) injury was studied using molecular biology experiments. RNA-seq and miRNA-omics analysis were performed to elucidate the mechanisms of NXT-Exo. Western blot and enzyme linked immunosorbent assay (ELISA) were used to validate the therapeutic target of NXT-Exo. Results NXT-Exo attenuated LPS-induced HMEC-1 injury by suppressing apoptosis, inflammation, oxidative stress, and endothelial dysfunction, while Ctl-Exo showed no effect. RNA-seq revealed the TLR4/TRIF/NF-κB signaling pathway might play a crucial role in NXT-Exo's effect. miRNA-omics suggested miR-382-5p as a pivotal mediator, and ELISA confirmed that i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research